Trials / Completed
CompletedNCT05397379
A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered HEC96719 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HEC96719 in non-cirrhotic NASH patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HEC96719 | Oral tablets |
| DRUG | Placebo | Comparator |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2023-09-05
- Completion
- 2023-09-05
- First posted
- 2022-05-31
- Last updated
- 2024-02-21
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05397379. Inclusion in this directory is not an endorsement.